CPRX files 8-K — Item 2.02 Results of Operations

Catalyst Pharmaceuticals, Inc. (CPRX, $3.8B market cap) filed an 8-K with the SEC disclosing Item 2.02 (Results of Operations and Financial Data) on May 11, 2026, at 16:33:41 ET, per EDGAR filing accession number 000119312526216929.

What Was Filed

Per SEC plain-language rules, Item 2.02 mandates public disclosure of material non-public information related to quarterly or annual financial results, including top-line metrics, earnings per share (EPS), and operational updates. The filing includes Exhibit 99.1, the accompanying earnings press release referenced in the SEC cover sheet, and was submitted concurrently with CPRX’s quarterly 10-Q filing for the three months ended March 31, 2026. No additional SEC items were included in the submission beyond the required results of operations disclosure.

The Disclosure

For a commercial-stage biotech focused on rare disease therapies, this Item 2.02 filing covers high-level quarterly financial performance, product sales for lead therapies, and core business updates. The filing aligns with the May 11 GlobeNewswire headline announcing Q1 2026 financial results, and follows the company’s May 7 announcement that it would cancel its scheduled Q1 earnings conference call and webcast.

Cross-Referenced Prior Signals

The Q1 2026 results show a slight revenue miss: actual revenue of $149.39 million versus consensus estimates of $149.52 million, with no reported EPS compared to a consensus estimate of $0.64 per share. This marks a shift from the prior three quarters, where CPRX beat both EPS and revenue estimates by double-digit margins. Analyst ratings have remained static since February 2026, with 7 Buy ratings and no Sell, Hold, or Strong Buy ratings across four consecutive monthly updates. No open-market insider transactions have been reported in the 90 days prior to the May 11 filing; the most recent Form4s, filed in January and February 2026, involved only M-exempt and in-kind share transfers with no cash exchange. As of December 31, 2025, CPRX had 376 institutional holders (a 10-person increase from the prior quarter), with institutional ownership of 84.8% of the company’s float, including 64 new positions, 190 increased positions, 126 reduced positions, and 51 fully closed positions.

Unanswered Data Points

1) A breakdown of sales for Firdapse, CPRX’s sole commercialized product, which is not included in the provided summary financial data. 2) The formal rationale for canceling the Q1 2026 earnings call, announced May 7 but not disclosed in the May 11 8-K. 3) Updated 2026 full-year guidance, a common inclusion in biotech Item 2.02 filings that is not referenced in the provided filing details.